| 23.93 0.84 (3.64%) | 08-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 27.97 |
1-year : | 32.67 |
| Resists | First : | 23.95 |
Second : | 27.97 |
| Pivot price | 21.73 |
|||
| Supports | First : | 19.98 |
Second : | 17.54 |
| MAs | MA(5) : | 22.79 |
MA(20) : | 21.14 |
| MA(100) : | 17.83  |
MA(250) : | 23.25 |
|
| MACD | MACD : | 1.1 |
Signal : | 1 |
| %K %D | K(14,3) : | 84.6 |
D(3) : | 76.8 |
| RSI | RSI(14): 70.2 |
|||
| 52-week | High : | 34.29 | Low : | 13.18 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ VRDN ] has closed below upper band by 15.2%. Bollinger Bands are 6.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 23.99 - 24.08 | 24.08 - 24.18 |
| Low: | 22.61 - 22.71 | 22.71 - 22.81 |
| Close: | 23.76 - 23.94 | 23.94 - 24.12 |
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
Wed, 19 Aug 2026
GSA Capital Partners LLP Invests $903,000 in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Tue, 18 Aug 2026
Viridian (NASDAQ: VRDN) CMO acquires 40K shares via option - stocktitan.net
Tue, 18 Aug 2026
93,414 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Merck & Co. Inc. - MarketBeat
Tue, 18 Aug 2026
1,175,906 Shares in Viridian Therapeutics, Inc. $VRDN Bought by Rice Hall James & Associates LLC - MarketBeat
Tue, 18 Aug 2026
VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval - Stocktwits
Fri, 14 Aug 2026
Viridian Therapeutics Stock Price Forecast. Should You Buy VRDN? - StockInvest.us
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 113 (M) |
| Held by Insiders | 1.0745e+008 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 15,020 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.0473e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -44 % |
| Return on Assets (ttm) | 460.5 % |
| Return on Equity (ttm) | -30.2 % |
| Qtrly Rev. Growth | 7.113e+007 % |
| Gross Profit (p.s.) | 107.64 |
| Sales Per Share | -65.33 |
| EBITDA (p.s.) | -3.01933e+008 |
| Qtrly Earnings Growth | -3.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -333 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.37 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 1.892e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|